Menstrual-cycle restoration (return of spontaneous menses or low FSH confirming ovarian activity) is reported in 30–50% of treated women. Pregnancy achievement (either spontaneously or via assisted fertility) occurs in 15–35% of treated women across published trials, though baseline fertility potential, age, and concomitant treatments substantially influence outcomes.
Thirty-five completed trials and 3 actively recruiting trials are registered for POI cell therapy, predominantly using autologous or allogeneic placental MSCs and fetal-derived cell preparations. Trial designs vary from direct ovarian injection to systemic intravenous infusion. Outcomes tracked include restored menstruation, improved hormone levels (oestradiol, FSH), pregnancy achievement, and ultrasound evidence of follicle development. Approximately 30–50% of treated women report return of menstrual cycles within 3–6 months; pregnancy rates (per cycle or per treatment) vary widely (10–40% in published small series) and are confounded by concurrent fertility treatments (in-vitro fertilisation, egg freezing).
Съм ли кандидат? → · Premature Ovarian Insufficiency: full overview → · Цена Преждевременна овариална недостатъчност → · Cost →
Медицински преглед от редакционния екип на StemCellAtlas с Dr Dmytro Stoyanov (Urologist · 31+ yrs clinical practice) на партньорската клиника Stem Plus (София), спрямо ISSCR, FDA и EMA указания. Educational information, not medical advice; figures indicative.
GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.
Безплатна медицинска оценка